<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">AMB</journal-id><journal-title-group><journal-title>Advances in Microbiology</journal-title></journal-title-group><issn pub-type="epub">2327-0810</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/AMB.2019.83016</article-id><article-id pub-id-type="publisher-id">AMB-32117</article-id><article-categories><subj-group subj-group-type="heading"><subject>AMB20190300000_77495604.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>生命科学</subject></subj-group></article-categories><title-group><article-title>
 
 
  土拉弗朗西斯菌的研究现况
  Current Status of Research on Francisella tularensis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苏</surname><given-names>超</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>鹤松</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>桂荣</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>志忠</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>大理大学公共卫生学院，云南 大理；云南省地方病防治所/云南省自然疫源性疾病防控技术重点实验室/云南省鼠疫防治研究中心/徐建国院士工作站，云南 大理</addr-line></aff><aff id="aff3"><addr-line>云南省地方病防治所/云南省自然疫源性疾病防控技术重点实验室/云南省鼠疫防治研究中心/徐建国院士工作站，云南 大理</addr-line></aff><aff id="aff4"><addr-line>云南省疾病预防控制中心，云南 昆明</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>23</day><month>07</month><year>2019</year></pub-date><volume>08</volume><issue>03</issue><fpage>130</fpage><lpage>138</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   土拉热，是由土拉弗朗西斯菌引起的一种人兽共患病。该病最早于1919年由E. Francis在美国的土拉县发现，因此被命名为土拉热。我国在1959年的黑龙江省报道了第一起人间感染。因其致病性强、易于传播的特点，被美国CDC列为A类生物恐怖病原体，因此对本病的深入研究具有重要的现实意义。本文从土拉弗氏菌的发现史、病原学特征、致病及传播机制、常见检测方法、疾病的诊断、临床表现及治疗、疫苗研究等几个方面进行了综述。 Tularemia is a zoonotic disease caused by Francisella tularensis. The disease was first discovered in 1919 by E. Francis in Tulla County in the United States, so it was named Tularemia. In 1959, our country reported the first human infections in Heilongjiang province. Due to its characteristics of high pathogenicity and easy transmission, it is regarded as a class A bioterrorism pathogen by the CDC of the United States. Therefore, the in-depth study of this disease has important practical significance. In this paper, we reviewed the discovery history, pathogenic characteristics, pathogenic and transmission mechanism, common detection methods, disease diagnosis, clinical manifestations and treatment, vaccine research, etc.
    
  
 
</p></abstract><kwd-group><kwd>土拉热，土拉弗朗西斯菌，研究现况，综述, Tularemia</kwd><kwd> Francisella tularensis</kwd><kwd> Research Status</kwd><kwd> Review</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>土拉弗朗西斯菌的研究现况<sup> </sup></title><p>苏超<sup>1,2</sup>，吴鹤松<sup>2</sup>，杨桂荣<sup>2</sup>，宋志忠<sup>3*</sup></p><p><sup>1</sup>大理大学公共卫生学院，云南 大理</p><p><sup>2</sup>云南省地方病防治所/云南省自然疫源性疾病防控技术重点实验室/云南省鼠疫防治研究中心/徐建国院士工作站，云南 大理</p><p><sup>3</sup>云南省疾病预防控制中心，云南 昆明</p><disp-formula id="hanspub.32117-formula42"><graphic xlink:href="//html.hanspub.org/file/4-2730157x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年8月22日；录用日期：2019年9月4日；发布日期：2019年9月11日</p><disp-formula id="hanspub.32117-formula43"><graphic xlink:href="//html.hanspub.org/file/4-2730157x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>土拉热，是由土拉弗朗西斯菌引起的一种人兽共患病。该病最早于1919年由E. Francis在美国的土拉县发现，因此被命名为土拉热。我国在1959年的黑龙江省报道了第一起人间感染。因其致病性强、易于传播的特点，被美国CDC列为A类生物恐怖病原体，因此对本病的深入研究具有重要的现实意义。本文从土拉弗氏菌的发现史、病原学特征、致病及传播机制、常见检测方法、疾病的诊断、临床表现及治疗、疫苗研究等几个方面进行了综述。</p><p>关键词 :土拉热，土拉弗朗西斯菌，研究现况，综述</p><disp-formula id="hanspub.32117-formula44"><graphic xlink:href="//html.hanspub.org/file/4-2730157x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-2730157x8_hanspub.png" /> <img src="//html.hanspub.org/file/4-2730157x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>土拉热，是由土拉弗朗西斯菌(简称土拉菌)经患病的野生动物、带菌的吸血昆虫和遭受细菌污染的水或食物等，所传播引起的人兽共患热性传染疾病，因为最初主要是在野生啮齿类动物特别是野兔中流行，故又被称之为野兔热或兔热病，多发生于北半球国家 [<xref ref-type="bibr" rid="hanspub.32117-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref2">2</xref>]。常突然起病，高热伴寒战、淋巴结肿大及毒血症症状，由于入侵途径较多、受累脏器轻重不一，故临床表现呈多样化。</p></sec><sec id="s4"><title>2. 土拉菌的发现史</title><p>土拉热的发现，包括致病因子的分离、致病因子与人类疾病的联系、组织病理学和流行病学的阐明是美国的一项重要成就。1906年旧金山大地震发生后，美国公共卫生所鼠疫实验室主任G. W. McCoy对灾区的地松鼠等鼠类的鼠疫病进行了细菌学调查。在一些地松鼠的样本中，带有鼠疫病的典型变化，但试图分离病原体的尝试失败了。在试用了更有营养的培养基后，MCCOY和CHAPIN成功的分离出了一种新的微生物 [<xref ref-type="bibr" rid="hanspub.32117-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref7">7</xref>]，并以美国加利福尼亚州中部的土拉县这一最初发现它的地方命名为土拉菌。在人类病例中，该病原首次是在伴有局部淋巴结肿大的结膜炎患者身上分离得到的 [<xref ref-type="bibr" rid="hanspub.32117-ref8">8</xref>]。</p><p>1919年，E. Francis作为公共卫生官员从华盛顿特区被派往犹他州调查鹿蝇热。随后从重症病人的血液中分离出了土拉菌，并对该疾病在鼠类、家兔以及人类中的病理改变进行了广泛的研究，由于后期从人体血液中也分离到了这种病菌，因此这种疾病便被命名为了土拉热。Francis发明了基于培养和血清学的土拉热诊断方法，同时描述了实验室感染病例，从而将该病菌确定为实验室危险病菌 [<xref ref-type="bibr" rid="hanspub.32117-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref11">11</xref>]。而后人为了纪念E. Francis在研究土拉菌上的历史成就，这种病菌便被正式更名为了Francisella tularensis (土拉弗朗西斯菌) [<xref ref-type="bibr" rid="hanspub.32117-ref12">12</xref>]。</p><p>1925年，在E. Francis对土拉病进行深入研究期间，Hachiro Ohara描述了日本的一种疾病，其临床表现与土拉病相似。后来Riki Ohara女士自愿成为实验对象，她让Ohara用一只染病兔子的身体组织在自己左手背表面涂抹，Ohara女士出现了典型的发烧和淋巴结肿大症状，并在淋巴结组织活检中，检出了细菌，随后被E. Francis确定为F. tularensis [<xref ref-type="bibr" rid="hanspub.32117-ref13">13</xref>]。</p><p>在我们国家，土拉菌的研究起步较晚，最早是于1957年从黄鼠的体内被分离得到的，而人间第一起土拉热病例是1959年在黑龙江省被报道的 [<xref ref-type="bibr" rid="hanspub.32117-ref14">14</xref>]。随后新疆自治区、西藏自治区、甘肃省等地也被相继证明存在着土拉热的自然疫源地 [<xref ref-type="bibr" rid="hanspub.32117-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref16">16</xref>]，并从这些地区的病人、媒介节肢动物、啮齿动物等体内分离到了相应的病原体。在1986年，山东省的某个肉类加工厂内突然暴发了人间疫情，共发生31个病例 [<xref ref-type="bibr" rid="hanspub.32117-ref17">17</xref>]。之后，在我国有关土拉热的人间疫情及动物疫情情况均鲜为报道，不知是否由于生态环境变化所导致既往的疫源地消失或处于静息状态，又或是由于人员、技术等条件的限制而未能对此病开展相关的诊断及监测。另外值得注意的是，该病诸如宿主动物感染情况及种类、疫源分布情况及类型、菌体分子生物学差异等众多流行病学问题目前尚未完全清楚，值得人们深入思考并开展相关的调查研究 [<xref ref-type="bibr" rid="hanspub.32117-ref18">18</xref>]。</p></sec><sec id="s5"><title>3. 病原学特征</title><p>土拉菌是一种革兰氏阴性、过氧化氢酶阳性、多形性和非运动性的球杆菌，是细胞内兼性病原体，可在巨噬细胞、肝细胞和上皮细胞等不同类型的细胞内生长 [<xref ref-type="bibr" rid="hanspub.32117-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref21">21</xref>]。它需要半胱氨酸或胱氨酸的生长环境，在适当的固体培养基(如含1%血红蛋白的胱氨酸心血琼脂培养基)上，培养2~4天后能形成明显的乳白色凸出菌落。能分解有限的碳水化合物，从而产酸，但不产气，并且不容易与其他革兰氏阴性菌通过常规诊断试剂盒进行鉴别。其细胞壁具有异常水平高的脂肪酸，在该属中具有独特的特征，野生菌株具有丰富的脂质囊，但既没有毒性也没有免疫原性 [<xref ref-type="bibr" rid="hanspub.32117-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref23">23</xref>]，这些特征可以通过气液色谱法进行识别 [<xref ref-type="bibr" rid="hanspub.32117-ref24">24</xref>]。另外该细菌对外界自然环境有很强的抵抗能力，根据研究发现，其在土壤、水、皮毛、肉中可以存活数十天，在动物的尸体当中甚至100余天仍能存活 [<xref ref-type="bibr" rid="hanspub.32117-ref25">25</xref>]。</p><p>土拉菌有四个亚种：A型土拉热亚种(F. tularensis subsp. tularensis)、B型全北区亚种(F. tularensis subsp. holarctica)、中亚细亚亚种(F. tularensis subsp. mediaasiatica) 和新凶手亚种(F. tularensis subsp. novicida) [<xref ref-type="bibr" rid="hanspub.32117-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref27">27</xref>]。其中A型和B型可以引起人类疾病，而subsp. mediaasiatica在人类中被认为是相对毒性较低的亚种，因为只有少数的已知病例是由该亚种引起，subsp. novicida对人类基本无致病性 [<xref ref-type="bibr" rid="hanspub.32117-ref28">28</xref>]。A型菌株主要分布于加拿大和美国，而B型菌株几乎遍布于包括欧洲在内的整个北半球 [<xref ref-type="bibr" rid="hanspub.32117-ref29">29</xref>]。所有的亚种中 F. tularensis subsp. tularensis的毒力是最强的，有研究表明在缺乏相应治疗药物或抗菌素的情况下，十个菌量就有可能导致急性、甚至致命性的病情 [<xref ref-type="bibr" rid="hanspub.32117-ref30">30</xref>]，而且被其感染后发病率高达30%~60% [<xref ref-type="bibr" rid="hanspub.32117-ref31">31</xref>]。基于这些特性，只要通过气溶胶途径被非常小的菌量感染既可能导致异常严重的病情甚至大面积的流行，并且该菌曾被前苏联、美国和日本等国家作为生物战剂研究，因此极有可能被用作气溶胶生物化学武器，因此被美国CDC作为长期开展“防生化恐怖”的重要监测目标，并被列为A类生物恐怖病原体 [<xref ref-type="bibr" rid="hanspub.32117-ref32">32</xref>]。</p></sec><sec id="s6"><title>4. 致病与传播机制</title><p>土拉菌的自然宿主媒介主要为蜱、兔、鼠等节肢动物和哺乳类动物 [<xref ref-type="bibr" rid="hanspub.32117-ref2">2</xref>]。</p><p>在欧洲，啮齿类哺乳动物和兔形目动物被认为是最主要的动物宿主 [<xref ref-type="bibr" rid="hanspub.32117-ref33">33</xref>]。人类可通过接触受感染的哺乳动物、节肢动物或受污染的水或食物而传播 [<xref ref-type="bibr" rid="hanspub.32117-ref34">34</xref>]，例如直接接触被感染的动物感染(通过皮肤破损、划痕或组织损伤)、通过吸血节肢动物(如跳蚤、虱子、蚊虫、臭虫、蚊子、扁虱)叮咬、通过饮用受污染的水、吃被污染的食物、或通过吸入带菌的尘埃 [<xref ref-type="bibr" rid="hanspub.32117-ref35">35</xref>]。同时，也有实验室获得性土拉病的报道 [<xref ref-type="bibr" rid="hanspub.32117-ref36">36</xref>]。</p><p>土拉菌侵入机体的一个显著的特点是能够通过几种途径诱导吞噬作用从而进入多种类型细胞，尤其是巨噬细胞，并在巨噬细胞中迅速逃离吞噬体，前往细胞质中大量复制 [<xref ref-type="bibr" rid="hanspub.32117-ref28">28</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref37">37</xref>]，通过吞噬体逃逸和胞质复制在吞噬细胞体内存活，最终导致炎性体激活和宿主细胞的死亡。因此，土拉菌的毒力源于它在受感染细胞，特别是巨噬细胞细胞质中大量繁殖的能力 [<xref ref-type="bibr" rid="hanspub.32117-ref38">38</xref>]。这些繁殖侵入过程需要弗朗西斯菌致病岛(FPI)的支持，它编码了一种VI型分泌系统(T6SS)，并在病菌感染细胞内时活跃，通过一种依赖T6SS分泌的外膜脂蛋白IgIE，从而在土拉菌的致病过程中起到重要的作用 [<xref ref-type="bibr" rid="hanspub.32117-ref39">39</xref>]。另外，C3补体是人体中必需的一种调理素，有研究发现它不仅能显著增加巨噬细胞对Schu S4的摄取，而且能诱导巨噬细胞的死亡，在调节巨噬细胞活性方面，C3补体调理作用对土拉菌的识别起到了非常重要的作用 [<xref ref-type="bibr" rid="hanspub.32117-ref40">40</xref>]。</p><p>近期有研究表明，肥胖也成为了感染土拉病的重要易感因素之一，因为肥胖个体基础瘦素表达的增加导致了持续低水平的炎症反应，使他们更容易感染土拉菌，并增加了免疫病理细胞因子风暴的产生。 [<xref ref-type="bibr" rid="hanspub.32117-ref41">41</xref>] 另外有数据显示，外膜蛋白TolC在调节宿主免疫反应和土拉菌毒力方面也发挥了保守和关键的作用，同时也强调了土拉菌发病机制中菌株和路径依赖存在着一定的差异 [<xref ref-type="bibr" rid="hanspub.32117-ref42">42</xref>]。</p></sec><sec id="s7"><title>5. 常用的检测方法</title><p>土拉热作为一种自然疫源性人兽共患传染疾病，目前在很多地区仍在流行，基于其可以通由气溶胶传播的特性，给防控治疗机构的检验鉴定等工作带来了巨大的困难。土拉菌的传统检验鉴定方法主要有常规分离培养 [<xref ref-type="bibr" rid="hanspub.32117-ref1">1</xref>] 、酶联免疫吸附实验 [<xref ref-type="bibr" rid="hanspub.32117-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref43">43</xref>] 、微量血液凝集试验 [<xref ref-type="bibr" rid="hanspub.32117-ref44">44</xref>] 、胶体金 [<xref ref-type="bibr" rid="hanspub.32117-ref45">45</xref>] 、普通PCR [<xref ref-type="bibr" rid="hanspub.32117-ref46">46</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref47">47</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref48">48</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref49">49</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref50">50</xref>] 等。而今，伴随着科学技术的不断发展以及基础医学研究技术的不断进步，开发出了众多新的检验检测鉴定方法，并被成功应用于包括土拉菌在内的微生物检验鉴定过程当中。例如荧光免疫技术 [<xref ref-type="bibr" rid="hanspub.32117-ref51">51</xref>] 、流式细胞技术 [<xref ref-type="bibr" rid="hanspub.32117-ref51">51</xref>] 、Real-time PCR [<xref ref-type="bibr" rid="hanspub.32117-ref52">52</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref53">53</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref54">54</xref>] 、核酸杂交 [<xref ref-type="bibr" rid="hanspub.32117-ref55">55</xref>] 、质谱分析 [<xref ref-type="bibr" rid="hanspub.32117-ref56">56</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref57">57</xref>] 、生物芯片 [<xref ref-type="bibr" rid="hanspub.32117-ref58">58</xref>] 、生物传感器 [<xref ref-type="bibr" rid="hanspub.32117-ref59">59</xref>] 、乳胶凝集试验 [<xref ref-type="bibr" rid="hanspub.32117-ref60">60</xref>] 等，这些检验检测技术在特异度和灵敏度方面都各具优势，特别是有的方法具备高通量和快速的优点，更加适合于检测时间要求高、样本量较大的工作，也为科研工作人员提供了更加丰富的研究技术手段 [<xref ref-type="bibr" rid="hanspub.32117-ref61">61</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref62">62</xref>]。</p><p>在分析鉴定不同亚种间种群差异方面，比较功能基因组学对阐明这些差异背后的一些分子机制提供了很好的帮助。比如，设计一种用于检测弗朗西斯菌多个物种/亚转录本的共享探针微阵列，就能够进行比较转录分析，这样就可能突出这些人类菌株相对发病机制中的关键差异，并且这种策略广泛的适应性，可以推广到其它亲缘关系较近菌种间的种间分析 [<xref ref-type="bibr" rid="hanspub.32117-ref63">63</xref>]。</p></sec><sec id="s8"><title>6. 土拉热的诊断、临床表现及治疗</title><p>根据世卫组织规定，确诊土拉病例需要分离培养，并通过抗原或DNA检测将培养物鉴定为土拉菌。而临床诊断实验室现有的商用生化鉴定系统不能准确鉴定土拉菌。此外，具有配对血清标本滴度的四倍差异(试管或微量凝集试验)或ELISA有显著性差异(至少有一个血清阳性)也可确诊 [<xref ref-type="bibr" rid="hanspub.32117-ref64">64</xref>]。因为土拉热的诊断较为困难，建议在有感染非典型微生物危险的患者中，在常规治疗没有明显效果时，可以怀疑为土拉热。正确的诊断需要高度的警惕心理，并对这种非常挑剔的细菌进行长期的血液培养和检测。</p><p>人类的临床表现主要取决于感染途径，随着感染途径的不同，其症状表现和严重程度也各不相同 [<xref ref-type="bibr" rid="hanspub.32117-ref65">65</xref>]。但一般较为典型的症状是头痛、发烧、腹泻和呼吸困难。表1描述了6种不同的典型临床表现形式 [<xref ref-type="bibr" rid="hanspub.32117-ref66">66</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref67">67</xref>]，而菌血症的发生往往与潜在的疾病有关，如糖尿病、高龄、酗酒或使用免疫抑制剂等 [<xref ref-type="bibr" rid="hanspub.32117-ref68">68</xref>]，在血液培养中分离到土拉菌的情况是非常罕见的。</p><p>严重的土拉菌病需要住院治疗，其一线治疗药物是口服氨基糖苷类。与多西环素相比，氨基糖苷类药物通常具有较低的最低抑菌浓度、杀菌效果和较低的治疗失败率 [<xref ref-type="bibr" rid="hanspub.32117-ref69">69</xref>]。在较轻的病例中，建议使用喹诺酮类药物、多西环素和氯霉素 [<xref ref-type="bibr" rid="hanspub.32117-ref64">64</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref70">70</xref>]。值得注意的是，土拉菌对包括碳青霉烯类在内的所有β-内酰胺类抗生素都具有耐药性 [<xref ref-type="bibr" rid="hanspub.32117-ref71">71</xref>]。最新发现一种治疗酒精依赖的药物二硫磺胺也可以抑制土拉菌的体外生长，同时有研究表明该药物可能适合作为土拉热的体内治疗药物，但还需进行进一步的研究 [<xref ref-type="bibr" rid="hanspub.32117-ref72">72</xref>]。</p></sec><sec id="s9"><title>7. 疫苗研究</title><p>由于土拉菌是一种具有高度传染性的细菌，同时有可能被用作生物武器，因此开发一种有效的疫苗</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Common clinical types of Tula fever [<xref ref-type="bibr" rid="hanspub.32117-ref66">66</xref>] [67</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >临床分型</th><th align="center" valign="middle" >获得途径</th></tr></thead><tr><td align="center" valign="middle" >腺型或淋巴溃疡型</td><td align="center" valign="middle" >携带被土拉菌污染的材料或接触染疫动物</td></tr><tr><td align="center" valign="middle" >眼腺型</td><td align="center" valign="middle" >通过受污染的手或灰尘接触眼部粘膜</td></tr><tr><td align="center" valign="middle" >口咽型</td><td align="center" valign="middle" >进食受感染的食物或水</td></tr><tr><td align="center" valign="middle" >呼吸型</td><td align="center" valign="middle" >吸入受污染的灰尘或作为口咽或伤寒形式的一种继发性表现</td></tr><tr><td align="center" valign="middle" >伤寒型</td><td align="center" valign="middle" >暂不清楚</td></tr></tbody></table></table-wrap><p>表1. 土拉热的常见临床类型 [<xref ref-type="bibr" rid="hanspub.32117-ref66">66</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref67">67</xref>]</p><p>是十分必要的 [<xref ref-type="bibr" rid="hanspub.32117-ref73">73</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref74">74</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref75">75</xref>]。为了开发一种能有效对抗土拉热的疫苗，人类尝试采用了多种不同的策略。最早存在的土拉热疫苗是Lee Foshay于1930年生产的一种灭活疫苗 [<xref ref-type="bibr" rid="hanspub.32117-ref76">76</xref>]。研究发现，以已杀灭的土拉菌为基础的制剂对毒性菌株的感染仅能产生微弱的保护作用，这种疫苗在志愿者测试中被证明可以预防土拉菌的皮肤感染，但不能预防呼吸系统感染 [<xref ref-type="bibr" rid="hanspub.32117-ref77">77</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref78">78</xref>]。之后在前苏联，Gaiskii和El’bert成功地将一株天然分离的土拉菌减毒成一种安全有效的疫苗株，并于1946年在苏联进行了大规模疫苗接种 [<xref ref-type="bibr" rid="hanspub.32117-ref79">79</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref80">80</xref>]。</p><p>1956年，一支含有活疫苗菌的安瓿从前苏联莫斯科的加玛利亚研究所，被转移到美国马里兰州德特里克堡的美国陆军传染病医学研究所。该研究所通过对动物模型的研究，选择了两种菌落变体中的一种，并对其进行人体安全性和有效性测试 [<xref ref-type="bibr" rid="hanspub.32117-ref81">81</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref82">82</xref>]，将其命名为F. tularensis活疫苗株(LVS)，用于高危人员的疫苗接种。LVS在志愿者测试中被观察到其对tularensis A型毒株的感染能够起到部分保护作用 [<xref ref-type="bibr" rid="hanspub.32117-ref83">83</xref>]。自从1960年德特里克堡引入LVS疫苗后，该地区高危人员的呼吸性土拉病发病率由5.7‰降至了0.27‰ [<xref ref-type="bibr" rid="hanspub.32117-ref84">84</xref>]，溃疡腺型土拉病人尽管症状和体征有所减轻，但是其发病率保持不变。遗憾的是，该活疫苗株未在美国或其他国家获得正式许可，因此排除了公共使用的可能，只能在研究中部分使用，其主要原因还是关于该细菌衰减源的不确定性和培养中的不稳定性 [<xref ref-type="bibr" rid="hanspub.32117-ref81">81</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref85">85</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref86">86</xref>]，在未来该疫苗能否大规模商用同样充满着众多的不确定性 [<xref ref-type="bibr" rid="hanspub.32117-ref32">32</xref>]。因此，研究一种新型的土拉热疫苗一直是近年来科学界的一个重要目标，最终希望能够开发出一种具有完全保护性的减毒疫苗，从而消除或进一步减少人们对疫苗安全性的担忧。</p><p>目前已经从LVS和剧毒的Schu S4菌株中衍生出许多减毒活突变体 [<xref ref-type="bibr" rid="hanspub.32117-ref86">86</xref>] [<xref ref-type="bibr" rid="hanspub.32117-ref87">87</xref>]，这些新的候选疫苗已在动物模型中显示出不同程度的效力，其中一些正在进一步开发并应用于人类。例如：有研究表明ΔpdpC可能作为一个候选疫苗，因为其研究数据表明其是一个安全并可致兔热病免疫的候选疫苗，适合进一步的临床开发 [<xref ref-type="bibr" rid="hanspub.32117-ref88">88</xref>]。另外也有研究发现，使用转基因O抗原的糖结合疫苗可诱导机体产生对土拉菌的保护性抗体，并且这种抗体能更好的识别那些与机体有更高亲和力的HMW和VHMW抗原上表达的长度依赖表位 [<xref ref-type="bibr" rid="hanspub.32117-ref89">89</xref>]。</p></sec><sec id="s10"><title>8. 研究展望</title><p>土拉菌的致病能力强，其气溶胶形态极易大面积广泛传播，是重要的生物恐怖病原体。但是由于我国研究起步较晚，本土主要菌种毒力较弱，导致人们对其认识不多，重视程度不够。</p><p>根据我国目前的研究，基本认为该病仅存在于我国的北方地区 [<xref ref-type="bibr" rid="hanspub.32117-ref62">62</xref>]，但是我国地形、气候、物种多样性各省各地区均存在很大差异，例如云南省基本具备从寒带到亚热带、热带的各种气候、海拔类型，动植物物种丰富，被称为动植物王国。而很多南方地区对该疾病并未开展过系统全面的调查，疾病分布情况其实并不明确，因此很有必要在南方地区开展系统的调查研究，以明确该病在我国的详细分布情况。</p><p>虽然目前对于土拉菌的众多问题还存在着盲区，但是幸运的是，随着当前分子生物学等技术的快速发展，为我们的研究提供了更加有力的工具与方法。例如对于土拉菌的毒力与疫苗的研究已经成为当下的热点，而且疫苗的研究有很好的应用前景，特别是作为一种“战备品”用以应对突发的挑战具有巨大的战略意义。另外，比较功能基因组学也为土拉菌的研究提供了新的方向。</p></sec><sec id="s11"><title>基金项目</title><p>本文章为国家自然科学基金项目，基金号：81560545。</p></sec><sec id="s12"><title>文章引用</title><p>苏 超,吴鹤松,杨桂荣,宋志忠. 土拉弗朗西斯菌的研究现况Current Status of Research on Francisella tularensis[J]. 微生物前沿, 2019, 08(03): 130-138. https://doi.org/10.12677/AMB.2019.83016</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.32117-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ellis, J., Oyston, P.C.F., Green, M. and Titball, R.W. (2002) Tularemia. Clinical Microbiology Reviews, 15, 631-646.&lt;br&gt;https://doi.org/10.1128/CMR.15.4.631-646.2002</mixed-citation></ref><ref id="hanspub.32117-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Tarnvik, A. (1989) Nature of Protective Immunity to Francisella tularensis. Reviews of Infectious Diseases, 11, 440-451. &lt;br&gt;https://doi.org/10.1093/clinids/11.3.440</mixed-citation></ref><ref id="hanspub.32117-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bennett, J.E., Dolin, R. and Blaser, M.J. (2019) Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. E-Book, Elsevier Health Sciences, Amsterdam.</mixed-citation></ref><ref id="hanspub.32117-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">McCoy, G.W. and Chapin, C.W. (1912) Further Observations on a Plague-Like Disease of Rodents with a Preliminary Note on the Causative Agent, Bacterium tularense. Journal of Infectious Diseases, 10, 61-72. &lt;br&gt;https://doi.org/10.1093/infdis/10.1.61</mixed-citation></ref><ref id="hanspub.32117-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">McCoy, G.W. and Chapin, C.W. (1912) Bacterium tularense, the Cause of a Plague-Like Disease of Rodents. Public Health Bulletin, 53, 17-23.</mixed-citation></ref><ref id="hanspub.32117-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Hansen, C.M., Vogler, A.J., Keim, P., Wagner, D.M. and Hueffer, K. (2011) Tularemia in Alaska, 1938-2010. Acta Veterinaria Scandinavica, 53, 61. &lt;br&gt;https://doi.org/10.1186/1751-0147-53-61</mixed-citation></ref><ref id="hanspub.32117-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Oyston, P.C. (2008) Francisella tularensis: Unravelling the Secrets of an Intracellular Pathogen. Journal of Medical Microbiology, 57, 921-930. &lt;br&gt;https://doi.org/10.1099/jmm.0.2008/000653-0</mixed-citation></ref><ref id="hanspub.32117-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Wherry, W.B. and Lamb, B.H. (2004) Infection of Man with Bacterium tularense. The Journal of Infectious Diseases, 189, 1321-1329. &lt;br&gt;https://doi.org/10.1093/infdis/189.7.1321</mixed-citation></ref><ref id="hanspub.32117-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Francis, E. (1922) Cultivation of Bacterium tularense on Three Additional Mediums New to This Organism. Public Health Reports, 37, 987-989. &lt;br&gt;https://doi.org/10.2307/4576373</mixed-citation></ref><ref id="hanspub.32117-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Francis, E. and Evans, A.C. (1926) Agglutination, Cross-Agglutination, and Agglutinin Absorption in Tularaemia. Public Health Reports, 41, 1273-1295. &lt;br&gt;https://doi.org/10.2307/4577917</mixed-citation></ref><ref id="hanspub.32117-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Gc, L.E.F. (1922) Six Cases of Tularemia Occurring in Laboratory Workers. Public Health Reports, 37, 392-413.&lt;br&gt;https://doi.org/10.2307/4576294</mixed-citation></ref><ref id="hanspub.32117-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Sw, R. (1983) Tularemia: What’s in a Name? ASM News, 49, 63-65.</mixed-citation></ref><ref id="hanspub.32117-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ohara, S.O. (1954) Studies on Yato-Byo (Ohara’s Disease, Tularemia in Japan), Report I. The Japanese Journal of Experimental Medicine, 24, 69-79.</mixed-citation></ref><ref id="hanspub.32117-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">康成贵, 王正夫, 韩文奎. 我国首次人间土拉伦菌病流行病学调查报告(摘要)[J]. 医学研究通讯, 1980(10): 11-12.</mixed-citation></ref><ref id="hanspub.32117-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">郭从厚, 曾庆国, 王舜臣, 等. 西藏地区土拉弗菌病初步调查[J]. 中华流行病学杂志, 1981, 2(3): 176-181.</mixed-citation></ref><ref id="hanspub.32117-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">孔昭敏, 陈国仕, 金根源, 等. 新疆蜱媒自然疫源性疾病的调查研究[J]. 疾病预防控制通报, 1987, 2(3): 1-4.</mixed-citation></ref><ref id="hanspub.32117-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">蓬增昌, 耿玉利, 肖永康, 等. 山东半岛首次土拉弗菌病爆发流行调查报告[J]. 中华流行病学杂志, 1987, 8(5): 261-263.</mixed-citation></ref><ref id="hanspub.32117-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">张芳, 刘玮, 何君, 等. 我国北方部分地区土拉弗菌感染宿主动物的分子流行病学研究[J]. 军事医学科学院院刊, 2006, 30(2): 131-134.</mixed-citation></ref><ref id="hanspub.32117-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Cowley, S.C. and Elkins, K.L. (2011) Immunity to Francisella. Frontiers in Microbiology, 2, 26.&lt;br&gt;https://doi.org/10.3389/fmicb.2011.00026</mixed-citation></ref><ref id="hanspub.32117-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">de Carvalho, I.L., Ms, N. and de Morais, J.D. (2009) Tularémia. Acta Médica Portuguesa, 3, 281-290.</mixed-citation></ref><ref id="hanspub.32117-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Foley, J.E. and Nieto, N.C. (2010) Tularemia. Veterinary Microbiology, 140, 332-338. &lt;br&gt;https://doi.org/10.1016/j.vetmic.2009.07.017</mixed-citation></ref><ref id="hanspub.32117-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Collier, L., Balows, A., and Sussman, M. (1998) Topley and Wilson’s Microbiology and Microbial Infections. John Wiley &amp; Sons, New York, 1347-1349.</mixed-citation></ref><ref id="hanspub.32117-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Petersen, J.M., Mead, P.S. and Schriefer, M.E. (2009) Francisella tularensis: An Arthropod-Borne Pathogen. Veterinary Research, 40, 7.</mixed-citation></ref><ref id="hanspub.32117-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Jantzen, E., Berdal, B.P. and Omland, T. (1979) Cellular Fatty Acid Composition of Francisella tularensis. Journal of Clinical Microbiology, 10, 928-930.</mixed-citation></ref><ref id="hanspub.32117-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">陈为民. 人兽共患病[M]. 武汉: 湖北科学技术出版社, 2006: 634.</mixed-citation></ref><ref id="hanspub.32117-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Beckstrom-Sternberg, S.M., Auerbach, R.K., Godbole, S., et al. (2007) Complete Genomic Characterization of a Pathogenic A.II Strain of Francisella tularensis Subspecies tularensis. PLoS ONE, 2, e947.&lt;br&gt;https://doi.org/10.1371/journal.pone.0000947</mixed-citation></ref><ref id="hanspub.32117-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Keim, P., Johansson, A. and Wagner, D.M. (2007) Molecular Epidemiology, Evolution, and Ecology of Francisella. Annals of the New York Academy of Sciences, 1105, 30-66. &lt;br&gt;https://doi.org/10.1196/annals.1409.011</mixed-citation></ref><ref id="hanspub.32117-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Celli, J. and Zahrt, T.C. (2013) Mechanisms of Francisella tularensis Intracellular Pathogenesis. Cold Spring Harbor Perspectives in Medicine, 3, a10314. &lt;br&gt;https://doi.org/10.1101/cshperspect.a010314</mixed-citation></ref><ref id="hanspub.32117-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Maurin, M. and Gyuranecz, M. (2016) Tularaemia: Clinical Aspects in Europe. The Lancet Infectious Diseases, 16, 113-124. &lt;br&gt;https://doi.org/10.1016/S1473-3099(15)00355-2</mixed-citation></ref><ref id="hanspub.32117-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Evans, M.E. (1985) Francisella tularensis. Infection Control, 6, 381-383.</mixed-citation></ref><ref id="hanspub.32117-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Gill, V. and Cunha, B.A. (1997) Tularemia Pneumonia. Seminars in Respiratory Infections, 12, 61-67.</mixed-citation></ref><ref id="hanspub.32117-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Dennis, D.T., Inglesby, T.V., Henderson, D.A., et al. (2001) Tularemia as a Biological Weapon: Medical and Public Health Management. The Journal of the American Medical Association, 285, 2763-2773. &lt;br&gt;https://doi.org/10.1001/jama.285.21.2763</mixed-citation></ref><ref id="hanspub.32117-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Rossow, H., Sissonen, S., Koskela, K.A., et al. (2014) Detection of Francisella tularensis in Voles in Finland. Vector-Borne and Zoonotic Diseases, 14, 193-198. &lt;br&gt;https://doi.org/10.1089/vbz.2012.1255</mixed-citation></ref><ref id="hanspub.32117-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Luque-Larena, J.J., Mougeot, F., Arroyo, B., et al. (2017) Irruptive Mammal Host Populations Shape Tularemia Epidemiology. PLOS Pathogens, 13, e1006622. &lt;br&gt;https://doi.org/10.1371/journal.ppat.1006622</mixed-citation></ref><ref id="hanspub.32117-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Forminska, K., Zasada, A.A., Rastawicki, W., et al. (2015) Increasing Role of Arthropod Bites in Tularaemia Transmission in Poland-Case Reports and Diagnostic Methods. Annals of Agricultural and Environmental Medicine, 22, 443-446. &lt;br&gt;https://doi.org/10.5604/12321966.1167711</mixed-citation></ref><ref id="hanspub.32117-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Roberts, R.R., Hota, B., Ahmad, I., et al. (2009) Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship. Clinical Infectious Diseases, 49, 1175-1184. &lt;br&gt;https://doi.org/10.1086/605630</mixed-citation></ref><ref id="hanspub.32117-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Pierini, L.M. (2006) Uptake of Serum-Opsonized Francisella tularensis by Macrophages Can Be Mediated by Class A Scavenger Receptors. Cellular Microbiology, 8, 1361-1370. &lt;br&gt;https://doi.org/10.1111/j.1462-5822.2006.00719.x</mixed-citation></ref><ref id="hanspub.32117-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Chong, A. and Celli, J. (2010) The Francisella Intracellular Life Cycle: Toward Molecular Mechanisms of Intracellular Survival and Proliferation. Frontiers in Microbiology, 1, 138. &lt;br&gt;https://doi.org/10.3389/fmicb.2010.00138</mixed-citation></ref><ref id="hanspub.32117-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Broms, J.E., Meyer, L. and Sjostedt, A. (2017) A Mutagenesis-Based Approach Identifies Amino Acids in the N-terminal part of Francisella tularensis IglE that Critically Control Type VI System-Mediated Secretion. Virulence, 8, 821-847. &lt;br&gt;https://doi.org/10.1080/21505594.2016.1258507</mixed-citation></ref><ref id="hanspub.32117-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Brock, S.R. and Parmely, M.J. (2017) Complement C3 as a Prompt for Human Macrophage Death during Infection with Francisella tularensis Strain Schu S4. Infection and Immunity, 85, 1-15. &lt;br&gt;https://doi.org/10.1128/IAI.00424-17</mixed-citation></ref><ref id="hanspub.32117-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Ramos, M.M., Palfreeman, M., Setzu, N., et al. (2018) Obesity Exacerbates the Cytokine Storm Elicited by Francisella tularensis Infection of Females and Is Associated with Increased Mortality. BioMed Research International, 2018, Article ID: 3412732. &lt;br&gt;https://doi.org/10.1155/2018/3412732</mixed-citation></ref><ref id="hanspub.32117-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Kopping, E.J., Doyle, C.R., Sampath, V. and Thanassi, D.G. (2019) Contributions of TolC Orthologs to Francisella tularensis Schu S4 Multidrug Resistance, Modulation of Host Cell Responses, and Virulence. Infection and Immunity, 87. &lt;br&gt;https://doi.org/10.1128/IAI.00823-18</mixed-citation></ref><ref id="hanspub.32117-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Grunow, R., Splettstoesser, W., Mcdonald, S., et al. (2000) Detection of Francisella tularensis in Biological Specimens Using a Capture Enzyme-Linked Immunosorbent Assay, an Immunochromatographic Handheld Assay, and a PCR. Clinical and Diagnostic Laboratory Immunology, 7, 86-90. &lt;br&gt;https://doi.org/10.1128/CDLI.7.1.86-90.2000</mixed-citation></ref><ref id="hanspub.32117-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Petersen, J.M., Schriefer, M.E., Gage, K.L., Montenieri, J.A., Carter, L.G., Stanley, M. and Chu, M.C. (2004) Methods for Enhanced Culture Recovery of Francisella tularensis. Applied and Environmental Microbiology, 70, 3733-3735. &lt;br&gt;https://doi.org/10.1128/AEM.70.6.3733-3735.2004</mixed-citation></ref><ref id="hanspub.32117-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Zeidner, N.S., Carter, L.G., Monteneiri, J.A., et al. (2004) An Outbreak of Francisella tularensis in Captive Prairie Dogs: An Immunohistochemical Analysis. Journal of Veterinary Diagnostic Investigation, 16, 150-152. &lt;br&gt;https://doi.org/10.1177/104063870401600210</mixed-citation></ref><ref id="hanspub.32117-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Aronova, N.V. and Pavlovich, N.V. (2000) The Use if Francisella tularensis Lipopolysaccharide in the Dot Solid Phase Enzyme Immunoassay. Zhurnalmikrobiologii, epidemiologii, iimmunobiologii, 5, 75-78.</mixed-citation></ref><ref id="hanspub.32117-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Berdal, B.P., Mehl, R., Haaheim, H., et al. (2000) Field Detection of Francisella tularensis. Scandinavian Journal of Infectious Diseases, 32, 287-291. &lt;br&gt;https://doi.org/10.1080/00365540050165938</mixed-citation></ref><ref id="hanspub.32117-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, J., Yang, R., Lu, J., et al. (1996) Detection of Francisella tularensis by the Polymerase Chain Reaction. Journal of Medical Microbiology, 45, 477-482. &lt;br&gt;https://doi.org/10.1099/00222615-45-6-477</mixed-citation></ref><ref id="hanspub.32117-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Porsch-Ozcurumez, M., Kischel, N., Priebe, H., et al. (2004) Comparison of Enzyme-Linked Immunosorbent Assay, Western Blotting, Microagglutination, Indirect Immunofluorescence Assay, and Flow Cytometry for Serological Diagnosis of Tularemia. Clinical and Diagnostic Laboratory Immunology, 11, 1008-1015. &lt;br&gt;https://doi.org/10.1128/CDLI.11.6.1008-1015.2004</mixed-citation></ref><ref id="hanspub.32117-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">李志清, 刘增加, 上官改珍, 等. 巢式-PCR检测蜱体中土拉弗氏菌的fopA基因及血清学调查[J]. 寄生虫与医学昆虫学报, 2014, 21(3): 160-164.</mixed-citation></ref><ref id="hanspub.32117-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Johansson, A., Ibrahim, A., Goransson, I., et al. (2000) Evaluation of PCR-Based Methods for Discrimination of Francisella Species and Subspecies and Development of a Specific PCR that Distinguishes the Two Major Subspecies of Francisella tularensis. Journal of Clinical Microbiology, 38, 4180-4185.</mixed-citation></ref><ref id="hanspub.32117-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Barns, S.M., Grow, C.C., Okinaka, R.T., Keim, P. and Kuske, C.R. (2005) Detection of Diverse New Francisella-Like Bacteria in Environmental Samples. Applied and Environmental Microbiology, 71, 5494-5500. &lt;br&gt;https://doi.org/10.1128/AEM.71.9.5494-5500.2005</mixed-citation></ref><ref id="hanspub.32117-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Sjostedt, A., Eriksson, U., Berglund, L. and T?rnvik, A. (1997) Detection of Francisella tularensis in Ulcers of Patients with Tularemia by PCR. Journal of Clinical Microbiology, 35, 1045-1048.</mixed-citation></ref><ref id="hanspub.32117-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Sreter-Lancz, Z., Szell, Z., Sreter, T. and Márialigeti, K. (2009) Detection of a Novel Francisella in Dermacentor reticulatus: A Need for Careful Evaluation of PCR-Based Identification of Francisella tularensis in Eurasian Ticks. Vector-Borne and Zoonotic Diseases, 9, 123-126. &lt;br&gt;https://doi.org/10.1089/vbz.2008.0010</mixed-citation></ref><ref id="hanspub.32117-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Tomaso, H., Scholz, H.C., Neubauer, H., et al. (2007) Real-Time PCR Using Hybridization Probes for the Rapid and Specific Identification of Francisella tularensis Subspecies Tularensis. Molecular and Cellular Probes, 21, 12-16.&lt;br&gt;https://doi.org/10.1016/j.mcp.2006.06.001</mixed-citation></ref><ref id="hanspub.32117-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">宫英, 强新, 李金海, 等. 土拉菌套式PCR检测技术的研究[J]. 现代预防医学, 2007, 34(23): 4576-4577.</mixed-citation></ref><ref id="hanspub.32117-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">张敏丽, 郭兆彪, 汪晓辉, 等. 土拉弗朗西斯氏菌PCR-EIA检测技术的研究[J]. 解放军预防医学杂志, 1999(4): 264-266.</mixed-citation></ref><ref id="hanspub.32117-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Fulop, M., Leslie, D. and Titball, R. (1996) A Rapid, Highly Sensitive Method for the Detection of Francisella tularensis in Clinical Samples Using the Polymerase Chain Reaction. The American Journal of Tropical Medicine and Hygiene, 54, 364-366. &lt;br&gt;https://doi.org/10.4269/ajtmh.1996.54.364</mixed-citation></ref><ref id="hanspub.32117-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Sellek, R., Jimenez, O., Aizpurua, C., et al. (2008) Recovery of Francisella tularensis from Soil Samples by Filtration and Detection by Real-Time PCR and cELISA. Journal of Environmental Monitoring, 10, 362-369. &lt;br&gt;https://doi.org/10.1039/b716608g</mixed-citation></ref><ref id="hanspub.32117-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">Rastawicki, W., Forminska, K., Zasada, A.A. (2018) Development and Evaluation of a Latex Agglutination Test for the Identification of Francisella tularensis Subspecies Pathogenic for Human. Polish Journal of Microbiology, 67, 241-244. &lt;br&gt;https://doi.org/10.21307/pjm-2018-030</mixed-citation></ref><ref id="hanspub.32117-ref61"><label>61</label><mixed-citation publication-type="other" xlink:type="simple">史清海. 土拉弗朗西斯氏菌、炭疽芽孢杆菌定量PCR检测技术的研究[D]: [硕士学位论文]. 北京: 中国人民解放军军事医学科学院, 2010.</mixed-citation></ref><ref id="hanspub.32117-ref62"><label>62</label><mixed-citation publication-type="other" xlink:type="simple">张芳. 我国土拉弗氏菌分子流行病学调查研究[D]: [博士学位论文]. 北京: 中国人民解放军军事医学科学院, 2008.</mixed-citation></ref><ref id="hanspub.32117-ref63"><label>63</label><mixed-citation publication-type="other" xlink:type="simple">Sarva, S.T., Waldo, R.H., Belland, R.J. and Klose, K.E. (2016) Comparative Transcriptional Analyses of Francisella tularensis and Francisella novicida. PLoS ONE, 11, e158631. &lt;br&gt;https://doi.org/10.1371/journal.pone.0158631</mixed-citation></ref><ref id="hanspub.32117-ref64"><label>64</label><mixed-citation publication-type="other" xlink:type="simple">WHO (2007) WHO Guidelines on Tularemia. Geneva, Switzerland.</mixed-citation></ref><ref id="hanspub.32117-ref65"><label>65</label><mixed-citation publication-type="other" xlink:type="simple">Eliasson, H., Broman, T., Forsman, M. and B?ck, E. (2006) Tularemia: Current Epidemiology and Disease Management. Infectious Disease Clinics of North America, 20, 289-311. &lt;br&gt;https://doi.org/10.1016/j.idc.2006.03.002</mixed-citation></ref><ref id="hanspub.32117-ref66"><label>66</label><mixed-citation publication-type="other" xlink:type="simple">Maurin, M., Pelloux, I., Brion, J.P., Del Ban?, J.-N. and Picard, A. (2011) Human Tularemia in France, 2006-2010. Clinical Infectious Diseases, 53, e133-e141. &lt;br&gt;https://doi.org/10.1093/cid/cir612</mixed-citation></ref><ref id="hanspub.32117-ref67"><label>67</label><mixed-citation publication-type="other" xlink:type="simple">Thomas, L.D. and Schaffner, W. (2010) Tularemia Pneumonia. Infectious Disease Clinics of North America, 24, 43-55.&lt;br&gt;https://doi.org/10.1016/j.idc.2009.10.012</mixed-citation></ref><ref id="hanspub.32117-ref68"><label>68</label><mixed-citation publication-type="other" xlink:type="simple">Karagoz, S., Kilic, S., Berk, E., et al. (2013) Francisella tularensis Bacteremia: Report of Two Cases and Review of the Literature. New Microbiologica, 36, 315-323.</mixed-citation></ref><ref id="hanspub.32117-ref69"><label>69</label><mixed-citation publication-type="other" xlink:type="simple">Caspar, Y., Hennebique, A. and Maurin, M. (2018) Antibiotic Susceptibility of Francisella tularensis Subsp. Holarctica Strains Isolated from Tularaemia Patients in France between 2006 and 2016. Journal of Antimicrobial Chemotherapy, 73, 687-691. &lt;br&gt;https://doi.org/10.1093/jac/dkx460</mixed-citation></ref><ref id="hanspub.32117-ref70"><label>70</label><mixed-citation publication-type="other" xlink:type="simple">Perez-Castrillon, J.L., Bachiller-Luque, P., Martin-Luquero, M., Mena-Martín, F.J. and Herreros, V. (2001) Tularemia Epidemic in Northwestern Spain: Clinical Description and Therapeutic Response. Clinical Infectious Diseases, 33, 573-576. &lt;br&gt;https://doi.org/10.1086/322601</mixed-citation></ref><ref id="hanspub.32117-ref71"><label>71</label><mixed-citation publication-type="other" xlink:type="simple">Hansen, B., Tilseth, R., Finjord, T. and Bruserud, ?. (2018) Francisella tularensis Bacteraemia Causing Multi-Organ Failure. Oxford Medical Case Reports, 2018, omy067. &lt;br&gt;https://doi.org/10.1093/omcr/omy067</mixed-citation></ref><ref id="hanspub.32117-ref72"><label>72</label><mixed-citation publication-type="other" xlink:type="simple">Hamblin, K.A., Flick-Smith, H., Barnes, K.B., et al. (2019) Disulfiram, an Alcohol Dependence Therapy, Can Inhibit the in vitro growth of Francisella tularensis. International Journal of Antimicrobial Agents, 54, 85-88. &lt;br&gt;https://doi.org/10.1016/j.ijantimicag.2019.04.002</mixed-citation></ref><ref id="hanspub.32117-ref73"><label>73</label><mixed-citation publication-type="other" xlink:type="simple">Bossi, P. and Bricaire, F. (2003) Tularemia, a Potential Bioterrorism Weapon. La Presse Médicale, 32, 1126-1130.</mixed-citation></ref><ref id="hanspub.32117-ref74"><label>74</label><mixed-citation publication-type="other" xlink:type="simple">Katz, L., Orr-Urteger, A., Brenner, B. and Hourvitz, A. (2002) Tularemia as a Biological Weapon. Harefuah, 141, 78-83+120.</mixed-citation></ref><ref id="hanspub.32117-ref75"><label>75</label><mixed-citation publication-type="other" xlink:type="simple">Mierzynska, D. and Hermanowska-Szpakowicz, T. (2002) Tularemia as a Potential Weapon of Bioterrorists. Medycynapracy, 53, 279-281.</mixed-citation></ref><ref id="hanspub.32117-ref76"><label>76</label><mixed-citation publication-type="other" xlink:type="simple">Foshay, L. (1932) Prophylactic Vaccination against Tularemia. American Journal of Clinical Pathology, 2, 7-10.&lt;br&gt;https://doi.org/10.1093/ajcp/2.1.7</mixed-citation></ref><ref id="hanspub.32117-ref77"><label>77</label><mixed-citation publication-type="other" xlink:type="simple">Saslaw, S., Eigelsbach, H.T., Prior, J.A., et al. (1961) Tularemia Vaccine Study. II. Respiratory Challenge. Archives of Internal Medicine, 107, 702-714. &lt;br&gt;https://doi.org/10.1001/archinte.1961.03620050068007</mixed-citation></ref><ref id="hanspub.32117-ref78"><label>78</label><mixed-citation publication-type="other" xlink:type="simple">Saslaw, S., Eigelsbach, H.T., Wilson, H.E., et al. (1961) Tularemia Vaccine Study. I. Intracutaneous Challenge. Archives of Internal Medicine, 107, 689-701.</mixed-citation></ref><ref id="hanspub.32117-ref79"><label>79</label><mixed-citation publication-type="other" xlink:type="simple">R P. (1967) History and Incidence of Tularemia in Soviet Union: A Review. The Institute of Contemporary Russian Studies, Fordham University, Bronx, New York.</mixed-citation></ref><ref id="hanspub.32117-ref80"><label>80</label><mixed-citation publication-type="other" xlink:type="simple">Tigertt, W.D. (1962) Soviet Viable Pasteurella Tularensis Vaccines. A Review of Selected Articles. Bacteriological Reviews, 26, 354-373.</mixed-citation></ref><ref id="hanspub.32117-ref81"><label>81</label><mixed-citation publication-type="other" xlink:type="simple">Eigelsbach, H.T. and Downs, C.M. (1961) Prophylactic Effectiveness of Live and Killed Tularemia Vaccines. I. Production of Vaccine and Evaluation in the White Mouse and Guinea Pig. The Journal of Immunology, 87, 415-425.</mixed-citation></ref><ref id="hanspub.32117-ref82"><label>82</label><mixed-citation publication-type="other" xlink:type="simple">Mccrumb, F.R. (1961) Aerosol Infection of Man with Pasteurella Tularensis. Bacteriological Reviews, 25, 262-267.</mixed-citation></ref><ref id="hanspub.32117-ref83"><label>83</label><mixed-citation publication-type="other" xlink:type="simple">Hornick, R.B. and Eigelsbach, H.T. (1966) Aerogenic Immunization of Man with Live Tularemia Vaccine. Bacteriological Reviews, 30, 532-538.</mixed-citation></ref><ref id="hanspub.32117-ref84"><label>84</label><mixed-citation publication-type="other" xlink:type="simple">Burke, D.S. (1977) Immunization against Tularemia: Analysis of the Effectiveness of Live Francisella tularensis Vaccine in Prevention of Laboratory-Acquired Tularemia. The Journal of Infectious Diseases, 135, 55-60.&lt;br&gt;https://doi.org/10.1093/infdis/135.1.55</mixed-citation></ref><ref id="hanspub.32117-ref85"><label>85</label><mixed-citation publication-type="other" xlink:type="simple">Hartley, G., Taylor, R., Prior, J., et al. (2006) Grey Variants of the Live Vaccine Strain of Francisella tularensis Lack Lipopolysaccharide O-Antigen, Show Reduced Ability to Survive in Macrophages and Do Not Induce Protective Immunity in Mice. Vaccine, 24, 989-996. &lt;br&gt;https://doi.org/10.1016/j.vaccine.2005.08.075</mixed-citation></ref><ref id="hanspub.32117-ref86"><label>86</label><mixed-citation publication-type="other" xlink:type="simple">Sunagar, R., Kumar, S., Franz, B.J. and Gosselin, E. (2016) Tularemia Vaccine Development: Paralysis or Progress? Vaccine, 6, 9-23. &lt;br&gt;https://doi.org/10.2147/VDT.S85545</mixed-citation></ref><ref id="hanspub.32117-ref87"><label>87</label><mixed-citation publication-type="other" xlink:type="simple">Marohn, M.E. and Barry, E.M. (2013) Live Attenuated Tularemia Vaccines: Recent Developments and Future Goals. Vaccine, 31, 3485-3491. &lt;br&gt;https://doi.org/10.1016/j.vaccine.2013.05.096</mixed-citation></ref><ref id="hanspub.32117-ref88"><label>88</label><mixed-citation publication-type="other" xlink:type="simple">Tian, D., Uda, A., Park, E.S., et al. (2018) Evaluation of Francisella tularensis ΔpdpC as a Candidate Live Attenuated Vaccine against Respiratory Challenge by a Virulent SCHU P9 Strain of Francisella tularensis in a C57BL/6J Mouse Model. Microbiology and Immunology, 62, 24-33. &lt;br&gt;https://doi.org/10.1111/1348-0421.12555</mixed-citation></ref><ref id="hanspub.32117-ref89"><label>89</label><mixed-citation publication-type="other" xlink:type="simple">Stefanetti, G., Okan, N., Fink, A., Gardner, E. and Kasper, D.L. (2019) Glycoconjugate Vaccine Using a Genetically Modified O Antigen Induces Protective Antibodies to Francisella tularensis. Proceedings of the National Academy of Sciences of the United States of America, 116, 7062-7070. &lt;br&gt;https://doi.org/10.1073/pnas.1900144116</mixed-citation></ref></ref-list></back></article>